Relation of Metabolic Rate of Omeprazole and Eradication of Helicobacter Pylori Infection

• Status: Completed
• Trial end date: 1998-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims of this study are (1) to evaluate the prevalence rate of PM of CYP2C19 in our country; (2) to evaluate the efficacy of dual therapy with different dose of omeprazole and amoxicillin; (3) to judge the relationship of genotype of CYP2C19 and the eradication rate of dual therapy in the peptic ulcer patients; (4) to try to find out a predictor of success of dual therapy and an optimal dose of dual therapy as first-line and rescue anti-Helicobacter pylori regimen.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborator: National Science Council, Taiwan
• Treatments: Amoxicillin; Omeprazole

Criteria

Inclusion Criteria:

• Male and female dyspeptic patients with H. pylori-positive duodenal ulcer.

Exclusion Criteria:

• Pregnant or nursing woman

• Serious concomitant illness

• Malignant tumor of any kind

• Serious bleeding during the course of this ulcer

• Previous gastric surgery

• Taking bismuth compounds, proton pump inhibitors, antibiotic or non-steroid anti-inflammatory drugs for at least one month prior to pretreatment endoscopy.